COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Shares Bought by Vivo Capital LLC

Key Points

• Vivo Capital LLC increased its stake in COMPASS Pathways PLC by 109.1% during the first quarter, owning approximately 3.62% of the company, valued at $9.6 million.
• COMPASS Pathways reported a quarterly EPS of ($0.38), missing analyst estimates, with projections anticipating an annual EPS of ($2.33).
• Analysts have an average price target of $16.29 for COMPASS Pathways, with Canaccord Genuity recently reaffirming a "buy" rating and a price target of $15.00.

Vivo Capital LLC grew its holdings in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 109.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,362,385 shares of the company's stock after purchasing an additional 1,754,385 shares during the quarter. COMPASS Pathways accounts for about 1.3% of Vivo Capital LLC's holdings, making the stock its 13th biggest holding. Vivo Capital LLC owned about 3.62% of COMPASS Pathways worth $9,616,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Virtus ETF Advisers LLC grew its stake in COMPASS Pathways by 21.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock worth $61,000 after purchasing an additional 2,840 shares in the last quarter. Flagship Harbor Advisors LLC raised its holdings in COMPASS Pathways by 27.7% in the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after acquiring an additional 3,134 shares in the last quarter. GAMMA Investing LLC raised its holdings in COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after acquiring an additional 5,003 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in COMPASS Pathways by 22.8% in the fourth quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock valued at $128,000 after acquiring an additional 6,297 shares in the last quarter. Finally, Barclays PLC raised its holdings in COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company's stock valued at $1,585,000 after acquiring an additional 8,718 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on CMPS shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $12.00 target price on shares of COMPASS Pathways in a report on Tuesday, May 27th. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 target price (down previously from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of COMPASS Pathways in a report on Friday, August 1st. Finally, HC Wainwright reduced their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, August 4th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $16.29.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock traded up $0.08 during trading on Friday, reaching $4.39. The company's stock had a trading volume of 840,147 shares, compared to its average volume of 2,160,169. The company has a 50-day moving average price of $4.01 and a two-hundred day moving average price of $3.83. The firm has a market cap of $421.18 million, a PE ratio of -2.39 and a beta of 2.17. COMPASS Pathways PLC Sponsored ADR has a fifty-two week low of $2.25 and a fifty-two week high of $8.54. The company has a current ratio of 8.82, a quick ratio of 8.82 and a debt-to-equity ratio of 0.16.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). On average, analysts forecast that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.